Why Constipation Is Making Patients Quit GLP-1 Medications (And How to Stay the Course)

GLP-1 medications — semaglutide, tirzepatide, and others — represent a genuine breakthrough in obesity and metabolic disease treatment. Clinical trials show meaningful, sustained weight loss. Cardiovascular outcomes data is compelling. For millions of patients, these medications are genuinely life-changing.

So why do so many people stop taking them?

The answer, increasingly, comes down to something unsexy: constipation. Not dramatic, dangerous side effects — just the chronic, grinding discomfort of a gut that won’t cooperate. And it’s driving a quiet discontinuation crisis in GLP-1 therapy that healthcare providers are only beginning to fully address.

---

The Scale of the Problem

Discontinuation rates for GLP-1 medications are higher than most people realize. Research published in 2026 found that a significant portion of patients stop their GLP-1 medication within the first 12 months — with gastrointestinal side effects, including constipation, cited as one of the top three reasons alongside cost and nausea.

This isn’t a minor inconvenience. Stopping GLP-1 therapy before reaching treatment goals means losing the metabolic benefits the medication was providing. For patients managing type 2 diabetes, it may mean worsening blood sugar control. For patients pursuing weight management, studies show that weight regain typically begins within weeks of stopping the medication.

The tragedy is that constipation — unlike cost or access issues — is almost always manageable. Patients are stopping a medication that’s working for them because nobody gave them the tools to handle a predictable, solvable side effect.

---

Why Constipation Hits GLP-1 Patients So Hard

To understand why constipation is such a significant quit trigger, you have to understand what it actually feels like to experience it on a GLP-1.

GLP-1 receptor agonists slow gastric emptying — food moves more slowly through your entire digestive system. This reduced motility means stool spends more time in the colon, absorbing water and becoming progressively harder and more difficult to pass. At the same time, the appetite suppression that makes these medications effective means patients are eating and drinking less, which further reduces bowel movement frequency and stool bulk.

The result isn’t just occasional irregularity. Many patients report:

• Going 4–7 days without a bowel movement
• Hard, dry stools that require significant straining
• Bloating and abdominal discomfort that compounds nausea (another common GLP-1 side effect)
• A general sense of physical misery that makes it hard to see the treatment as “working”

When you feel terrible every day, the rational response is to stop whatever is making you feel terrible. Even if that thing is also improving your A1C and helping you lose 15 pounds.

---

The Communication Gap

Here’s what makes this problem worse: most patients aren’t warned adequately about constipation before they start GLP-1 therapy.

Nausea gets the attention. Patients are counseled about nausea, given anti-nausea strategies, told to expect it in the first few weeks. But constipation? It often gets a single line in the medication guide — or nothing at all.

A patient who develops constipation and hasn’t been prepared for it may:

1. Assume something is wrong beyond normal side effects
2. Feel embarrassed discussing it with their provider
3. Try home remedies that don’t work (or make it worse)
4. Conclude that they “can’t tolerate” the medication and stop

This discontinuation often happens without a phone call to the prescriber. The patient just stops refilling the prescription. By the time the provider notices, weeks or months have passed — and the window for intervention is gone.

---

What Staying on GLP-1s Is Actually Worth

Before we talk about solutions, it’s worth pausing on what patients lose when they quit due to constipation.

For weight management: GLP-1 medications produce meaningful weight loss in most patients — often 10–20% of body weight with sustained use. This isn’t cosmetic. Sustained weight reduction of this magnitude reduces risk of cardiovascular disease, type 2 diabetes, sleep apnea, osteoarthritis, and certain cancers. That effect disappears when the medication stops.

For type 2 diabetes: Semaglutide has been shown in large trials (SUSTAIN-6, SOUL) to reduce cardiovascular events in patients with type 2 diabetes and established cardiovascular disease. The SELECT trial demonstrated a 20% reduction in major cardiovascular events in patients with obesity but without diabetes. These are hard outcomes — not just numbers on a lab report.

For metabolic health broadly: GLP-1 medications are being studied for nonalcoholic fatty liver disease, polycystic ovary syndrome, and other metabolic conditions. The emerging evidence is compelling. Every patient who stops therapy early due to manageable side effects is losing access to those benefits.

This context matters. Constipation is not a trivial issue to dismiss — but it is a solvable one, and the stakes for solving it are high.

---

Practical Strategies That Keep Patients on Therapy

The good news: patients who receive proactive, specific guidance on managing constipation have much better adherence rates. Here’s what actually helps.

Increase Fiber Intentionally

Because GLP-1 patients eat less, they often inadvertently reduce their fiber intake. The solution isn’t to eat more — it’s to make the calories you do eat more fiber-dense.

• Psyllium husk (1 tsp in water, morning): 5–7g soluble fiber, inexpensive, highly effective
• Chia seeds (2 tbsp): 10g fiber with minimal volume
• Ground flaxseed: adds fiber and anti-inflammatory omega-3s
• Cooked legumes: chickpeas, lentils, black beans are fiber-dense and easy to tolerate in small portions

Target 25–35g daily. Increase gradually — 5g per week — to avoid transitional bloating.

Hydrate Aggressively

Aim for 64–80 oz of water daily. Drink 16 oz of warm water first thing in the morning before coffee — this single habit has an outsize effect on morning bowel regularity. Warm liquid stimulates the gastrocolic reflex (the nerve reflex that triggers bowel contractions after eating or drinking).

Move After Meals

A 15–20 minute walk after meals is one of the most evidence-backed interventions for improving gut transit time. It doesn’t have to be vigorous — moderate walking is sufficient to meaningfully speed up bowel movements.

Use Osmotic Laxatives When Needed

Polyethylene glycol (MiraLAX) is a safe, non-habit-forming option for when constipation stalls for more than 2–3 days. One capful in any beverage, 1–3 times per week as needed, is a practical bridge while dietary strategies take effect.

Consider Magnesium Citrate

200–400mg of magnesium citrate at bedtime helps draw water into the intestines and supports natural bowel contractions. Many patients notice improvement within 1–2 weeks.

Talk to Your Prescriber

This is the most important strategy — and the one most patients skip. Prescribers can:

• Slow dose escalation to allow the gut to adjust
• Recommend specific interventions based on your health history
• Rule out other causes
• Reassure you that this is a known, manageable side effect — not a reason to stop

If you’re struggling with constipation on a GLP-1, please tell your provider. They want to help you stay on therapy. That’s the goal.

---

What Healthcare Providers Can Do

If you’re a healthcare provider reading this, the message is straightforward: proactive patient education on constipation at the time of GLP-1 initiation improves adherence.

Consider:

• Explicitly counseling patients that constipation may occur, especially at dose escalations
• Providing written resources on fiber, hydration, and laxative options before the first injection
• Asking about bowel habits at follow-up appointments (patients rarely volunteer this)
• Normalizing the conversation — constipation is a medical side effect, not something to be embarrassed about

Patients who feel prepared for a side effect tolerate it far better than patients who are blindsided by it. A five-minute conversation at initiation can prevent a premature discontinuation six weeks later.

---

You’re Not Alone — and You Don’t Have to Stop

If you’re currently struggling with constipation on a GLP-1 medication, the most important thing to know is this: you are not alone, and you do not have to stop your medication.

Constipation on GLP-1s is common, predictable, and — with the right approach — manageable for the vast majority of patients. The strategies in this post work. They work best when combined and implemented consistently from the start of therapy.

Our GLP-1 Constipation Relief Guide was created specifically for this moment — for patients who are struggling with this side effect and looking for real, evidence-based answers. It covers the full week-by-week protocol, supplement stack, dietary adjustments, and guidance on what to tell your prescriber so you can stay on your medication and keep moving toward your health goals.

The medication is working. Don’t let constipation be the reason you stop.

---

FlowWell creates evidence-based educational resources for patients on GLP-1 medications. Our content is designed to support — not replace — the guidance of your healthcare provider.